Vadim Koshkin

Vadim Koshkin is a genitourinary medical oncologist at the University of California San Francisco (UCSF), specializing in bladder, prostate, kidney, and testicular cancers. His work focuses on clinical and translational research, particularly the design of clinical trials and the discovery of biomarkers and treatment targets for genitourinary malignancies.

• Education: BA in Cognitive Science (University of Pennsylvania, 2007), MD (University of Chicago, 2012), Intern and Resident in Internal Medicine (University of Michigan Health System, 2013-2015), Fellow in Hematology-Oncology (Cleveland Clinic, 2018).

His research spans multiple areas in genitourinary oncology, including immunotherapy (e.g., checkpoint inhibitors, combination therapies), biomarker discovery (e.g., DLL3, HSD3B1 variants), and clinical trial design for cisplatin-ineligible patients, neoadjuvant therapies, and treatment sequencing. Key themes include improving outcomes for advanced bladder and prostate cancers through precision medicine and translational studies.

The 15 most recent publications highlight his expertise in urothelial and prostate cancer research, with recurring focus on immune checkpoint inhibitors, biomarker validation, and clinical trial outcomes. His work addresses challenges in renal function adaptation, non-clear cell renal cancer, and small-cell bladder cancer.

Scientific Awards:
• Junior Clinical Investigator Award (Helen Diller Family Comprehensive Cancer Center, 2019)
• John Quale Travel Fellowship (BCAN Bladder Cancer Think Tank, 2017)
• Young Investigator Abstract Award (International Kidney Cancer Symposium, 2017)
• Conquer Cancer Foundation Merit Award (ASCO 2017)
• Keith Edson Scholarship (2009)

As a Principal Investigator for the Prostate Cancer Foundation-funded study on CDK4/6 inhibition and PSMA-targeted radioligand therapy (2021-2024), he drives innovative research. While no specific lab or team details are provided, his collaborations with institutions like Cleveland Clinic, University of Michigan, and UCSF underscore his multidisciplinary approach.